В това отворено писмо бихме искали да изложим становището на лекарите медицински онколози, членуващи в Клуб Млад Онколог относно наскоро въведените лимити за медицински дейности и лекарства за онкологично болни пациенти. Противно нa тезата, че „няма как да стане по-лошо здравеопазването в България“, НЗОК, БЛС и МЗ ни демонстрират противното! Отговорността за лечението и живота [...]
Date: 10 Mar 2015 Topic: Palliative and supportive care On 6 March 2015 the US Food and Drug Administration (FDA) approved filgrastim-sndz (Zarxio), the first biosimilar product approved in the United States. Sandoz Inc.’s Zarxio is biosimilar to Amgen Inc.’s Neupogen (filgrastim), which was originally licensed in 1991. Zarxio is approved for the same indications [...]
Pancreatic cancer mutational landscape Date: 04 Mar 2015 Topic: Translational research / Gastrointestinal cancers The researchers performed whole-genome sequencing and copy number variation analysis of 100 samples to reveal mutational landscape of pancreatic ductal adenocarcinomas. Their findings led to classification of pancreatic ductal adenocarcinomas into 4 subtypes with potential clinical utility. The team of international [...]
Date: 03 Nov 2014 Topic: Genitourinary cancers / Translational research New research by the international Cancer Genomics of the Kidney consortium (CAGEKID) reveals an important connection between clear cell renal cell cancer (ccRCC) and exposure to aristolochic acid, an ingredient in some herbal remedies. The findings, published in Nature Communications, have important implications for public [...]
Date: 30 Oct 2014 Topic: Translational research / Lung and other thoracic tumours / Anticancer agents & Biologic therapy David Carbone David Carbone Mutations in the epidermal growth factor receptor (EGFR) are the most common actionable genetic abnormalities yet discovered in lung cancer. However, targeting these mutations with kinase inhibitors is not curative in advanced [...]
Women who received trastuzumab as part of standard treatment show greatest benefit Date: 10 Sep 2014Topic: Breast cancer / Immuno-oncology A new breast cancer vaccine candidate, GP2, provides further evidence of the potential of immunotherapy in preventing disease recurrence. This is especially the case for high-risk patients when it is administered after completing trastuzumab treatment. [...]
ASCO issues evidenced-based information for management of patients with HER2 negative or HER2 status unknown advanced breast cancer Date: 09 Sep 2014 Topic: Breast cancer / Anticancer agents & Biologic therapy The American Society of Clinical Oncology (ASCO) issued on 2 September 2014 a new clinical practice guideline on chemotherapy and targeted therapy for [...]